Confirming the validity of the ARC-HBR criteria in patients presenting with ACS: the first step in reducing bleeding risk
Rev Esp Cardiol (Engl Ed). 2022 May;75(5):360-363.
doi: 10.1016/j.rec.2021.11.005.
Epub 2022 Jan 31.
[Article in
English,
Spanish]
Affiliations
- 1 Cardiovascular Research Institute Dublin and Department of Cardiology, Mater Private Network, Dublin, Ireland; School of Medicine, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
- 2 Cardiovascular Department, Hôpital de la Tour, Geneva, Switzerland; European Cardiovascular Research Centre (CERC), Massy, Paris, France. Electronic address: philip.urban@latour.ch.
No abstract available
MeSH terms
-
Humans
-
Percutaneous Coronary Intervention*
-
Platelet Aggregation Inhibitors
-
Risk Assessment
-
Risk Factors
-
Treatment Outcome
Substances
-
Platelet Aggregation Inhibitors